Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  darinaparsin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-9 of 9 for your search:
Start Over
Study of ZIO-101 in Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGL2001, NCT00303199
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGL2005, NCT00423306
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGL2001b, NCT00423644
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGL2003, NCT00421213
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGC1001, NCT00591422
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGC1002, NCT00592163
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGC1004, NCT01139346
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SP-02L01, NCT01435863
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SP-02L03, NCT01689220
Start Over